As the life sciences sector powers ahead, fuelled by funding for further research into Covid and other health priorities, construction and refurbishment projects will be a core area of activity for the sector as it scales-up and diversifies its work. Competition among pharmaceutical giants has always been fierce and businesses in the sector will now gain an advantage if they can assess their performance in terms of real estate against peers. But how to do it in such a competitive industry and one where each construction and refurbishment project is highly bespoke?

There is a common perception that so diverse are life science real estate facilities that meaningful benchmarking is impossible. In fact, benchmarking life sciences real estate projects can be done, and Linesight is proving it with a pioneering new initiative involving sixteen of the world’s leading life sciences companies, including Pfizer and AstraZeneca.